A. H. Strickland

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 562 citations · Full text

Medicine, Oncology, Pharmacology +11

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Marc Peeters, Timothy Price, Andrés Cervantes et al. · Annals of Oncology · 2013 · 220 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies

Gargi Patel, Kunal Jain, Rajiv Kumar et al. · Supportive Care in Cancer · 2013 · 148 citations

Medicine, Oncology, Surgery +3

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

Niall C. Tebbutt, Michelle M. Cummins, T. Sourjina et al. · British Journal of Cancer · 2010 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

Marc Peeters, A. H. Strickland, Mikhail Lichinitser et al. · British Journal of Cancer · 2013 · 79 citations · Full text

Medicine, Oncology, Pharmacology +10